Serum urate: the end product of purine breakdown
Uric acid blood testing measures urate, the end product of purine breakdown. Purines come from the nucleic acids in your cells and from food. As cells turn over and purines are recycled or degraded, enzymes convert them through hypoxanthine and xanthine to uric acid (urate), mainly via xanthine oxidase in the liver and intestinal tissues. Urate then circulates in the bloodstream and is carried to the kidneys for clearance, with a smaller portion eliminated through the gut. The test captures how much urate is present in your blood at that time.
Urate is primarily a waste-handling molecule, but it also serves as a major antioxidant in human plasma. Its blood level reflects the balance between production (purine turnover, cell breakdown, dietary purines) and removal (kidney filtration with reabsorption and secretion, plus intestinal excretion). Because urate can form crystals under certain conditions (monosodium urate), the circulating level indicates the body's overall load of this solute and the demands placed on its clearance systems.
Why measuring urate matters across joints, kidneys, and vessels
Uric acid is the end-product of purine breakdown and a workload marker for the kidneys. In the bloodstream it can act as an antioxidant, yet inside tissues and at high levels it becomes pro-oxidative and crystal-forming. That dual nature is why it touches joints (gout), kidneys (stones and filtration), blood vessels (endothelial function), and metabolism.
A uric acid (serum urate) blood test measures the circulating end product of purine breakdown. It reflects how much your body is producing (cell turnover and liver metabolism via xanthine oxidoreductase) and how well your kidneys are clearing it (filtration and tubular handling). Levels connect to risk of gout and kidney stones and track with cardiometabolic, renal, and pregnancy physiology.
Reading high, low, and mid-range urate
Most labs set reference ranges in the mid-single digits—typically a bit higher in adult men than in women, with children lower and postmenopausal women trending upward. For long-term health, values in the middle of the range are generally considered most favorable. Being in range suggests balanced purine turnover and kidney handling, steadier redox signaling, and lower risk of crystal formation. Reference intervals differ by sex and age (men higher; premenopausal women lower; levels rise after menopause). Observational data suggest the lower-to-mid part of the range is often associated with favorable vascular and metabolic profiles. In the bloodstream, urate can act as an antioxidant, while inside tissues it can promote oxidative stress and inflammation.
When values run low, the body may be producing less uric acid (rare enzyme defects, severe liver disease, very low purine availability) or losing more through the kidneys (renal tubular transport defects). Low values usually reflect increased kidney loss or reduced production. Common settings include excess antidiuretic hormone with dilution and uricosuria (SIADH), proximal tubule dysfunction (Fanconi-type), or medications that block urate production; rare genetic defects (xanthinuria) do the same. Early pregnancy often lowers urate because kidney clearance rises. Early pregnancy often shows lower uric acid physiologically. Many people feel fine, but very low levels can reduce circulating antioxidant capacity. Effects are often subtle, though very low urate may signal a reduced circulating antioxidant pool or an underlying sodium-water imbalance. In inherited renal hypouricemia, high urinary urate can trigger exercise-induced flank pain, stones, or acute kidney injury. Children with genetic forms may present this way.
When values run high, either production is up (high cell turnover states such as psoriasis or hematologic disorders) or kidney excretion is down (impaired filtration, insulin resistance). High values usually reflect renal underexcretion or overproduction. Underexcretion occurs with reduced filtration, insulin resistance, and diuretic or calcineurin-inhibitor exposure; overproduction appears with rapid cell turnover (psoriasis, hematologic disorders) or tumor lysis. Symptoms can include gout flares and uric acid stones; chronic elevation is linked to declining kidney function, hypertension, and cardiometabolic risk. System effects include gout, uric acid stones, endothelial dysfunction, hypertension, fatty liver, and faster kidney disease progression. Men are affected more often; in late pregnancy, higher urate aligns with preeclampsia risk and fetal growth restriction. In late pregnancy, higher urate aligns with preeclampsia risk.
Sex, pregnancy, diet, and medication effects on urate
Interpretation varies with sex, age, pregnancy stage, acute illness, and medications (diuretics, low-dose aspirin, niacin increase; high-dose aspirin and uricosurics decrease; xanthine oxidase inhibitors lower production). Fasting is not required; modest diurnal and lab-to-lab variation exists.
Pairing urate with kidney function and metabolic markers
Big picture: uric acid integrates purine metabolism, renal handling, vascular biology, and insulin signaling. Persistently unbalanced levels—especially high—track with gout, nephrolithiasis, chronic kidney disease, and cardiovascular events, while very low levels can uncover rare renal or metabolic disorders.
FAQs
Uric Acid testing measures the concentration of uric acid in your blood to reflect purine metabolism and elimination. It helps assess risk for gout, kidney stones, and broader metabolic strain.
Testing detects silent elevations, sets a personal baseline, and shows how diet, alcohol, fructose, hydration, weight change, and medications affect your levels over time.
Frequency depends on your results and risk factors. Retest periodically, and more often if levels are high, symptoms occur, or you change diet, alcohol intake, weight, or medications.
Dietary purines, beer and spirits, fructose-sweetened drinks, dehydration, crash dieting, body weight, kidney function, diuretics, and low-dose aspirin can all influence levels.
Typically no special preparation is required. Staying well hydrated and avoiding unusual short-term changes (like crash dieting) helps helps support a representative result.
Superpower currently offers at-home blood testing in the following states: Alabama, Arizona, California, Colorado, Connecticut, Delaware, District of Columbia, Florida, Georgia, Idaho, Illinois, Indiana, Kansas, Maine, Maryland, Massachusetts, Michigan, Minnesota, Missouri, Montana, Nebraska, Nevada, New Hampshire, New Jersey, New Mexico, New York, North Carolina, Ohio, Oklahoma, Oregon, Pennsylvania, South Carolina, Tennessee, Texas, Utah, Vermont, Virginia, Washington, West Virginia, and Wisconsin.
We’re actively expanding nationwide, with new states being added regularly. If your state isn’t listed yet, stay tuned.
References
- Maiuolo, J., Oppedisano, F., Gratteri, S., Muscoli, C., & Mollace, V. (2016). Regulation of uric acid metabolism and excretion. International Journal of Cardiology, 213, 8-14. https://doi.org/10.1016/j.ijcard.2015.08.109
- Dalbeth, N., Gosling, A. L., Gaffo, A., & Abhishek, A. (2021). Gout. Lancet, 397(10287), 1843-1855. https://doi.org/10.1016/S0140-6736(21)00569-9
- Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. (2024). KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney International, 105(4S), S117-S314. https://doi.org/10.1016/j.kint.2023.10.018
- Zhao, X., An, X., Yang, C., Sun, W., Ji, H., & Lian, F. (2023). The crucial role and mechanism of insulin resistance in metabolic disease. Frontiers in Endocrinology, 14, 1149239. https://doi.org/10.3389/fendo.2023.1149239
- Inker, L. A., Eneanya, N. D., Coresh, J., Tighiouart, H., Wang, D., Sang, Y., Crews, D. C., Doria, A., Estrella, M. M., Froissart, M., Grams, M. E., Greene, T., Grubb, A., Gudnason, V., Gutiérrez, O. M., Kalil, R., Karger, A. B., Mauer, M., Navis, G., ... Levey, A. S. (2021). New creatinine- and cystatin C-based equations to estimate GFR without race. The New England Journal of Medicine, 385(19), 1737-1749. https://doi.org/10.1056/NEJMoa2102953






































.avif)
